HAYA Therapeutics Appoints Jordan Shin, M.D., Ph.D. as Chief Medical Officer
Slice of Healthcare Team
09/13/2024
Key Highlights
- HAYA Therapeutics appoints Dr. Jordan Shin as Chief Medical Officer.
- Dr. Shin brings over a decade of experience in cardiovascular and lung translational medicine.
- He will lead the clinical development of HTX-001 for non-obstructive hypertrophic cardiomyopathy.
- Prior leadership roles at LEXEO Therapeutics and Renovacor, and academic tenure at Harvard Medical School.
Source: Business Wire
Notable Quotes
Expert Insights
Share Your Expert Insights
Have relevant experience or professional perspective? Add your thoughtful insights to this article.
